Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Jun 22, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well a treatment called glofitamab works for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma, which is a type of cancer that affects the lymphatic system. The main goal of the study is to see how many patients respond completely to the treatment after receiving it through a special program designed to help those who have not had success with other treatments. The study is currently recruiting participants, and anyone aged 18 or older who has received at least one dose of glofitamab from March 2022 to September 2023 may be eligible to join.

If you or a family member participate in this trial, you can expect to have your health monitored for at least a year after receiving the treatment, unless there are complications like passing away or being unreachable. This study helps researchers gather data to better understand how effective glofitamab is, which could benefit future patients with similar conditions. It's important to know that this trial does not have any specific exclusions, meaning more people may qualify to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who received glofitamab according to Compassionate Use Program AG42296
• • 2. Age \> 18 years
• • 3. Patients who received at least one dose of glofitamab between March 2022 and September 2023 in the context of the compassionate use program and who completed at least 1 year of observation after last glofitamab administration unless the patient died or was lost to follow up
• • 4. Patients who provided their consent according to local regulation to collect their data for study purposes, dead patients or patients lost to follow up for which any attempt has been made to collect their consent, according to local regulation on data privacy
• Exclusion Criteria:
• • None